10:16 AM EDT, 03/13/2026 (MT Newswires) -- NervGen Pharma ( NGEN ) announced after markets closed on Thursday that its board elected to voluntarily delist its common shares from TSX Venture Exchange (TSXV), effective at the close of markets on March 16.

The company, following a comprehensive evaluation, said it determined that maintaining a dual listing on TSXV does not justify the associated costs and administrative needs. All shareholders, including Canadian shareholders, will continue to maintain full trading access of their common shares on Nasdaq.

In connection with the voluntary delisting from TSXV, the company has cancelled its previously announced at-the-market equity program, launched on Dec. 19, 2025. The company had issued 245 common shares under the ATM program, from Jan. 1, through March 12, at a weighted average price of $6.20 per common share, for proceeds of $1,489.

Shares of the company were last seen down 0.2% at $5.25 on the TSXV.

Price: 5.23, Change: -0.03, Percent Change: -0.57